Data Confirming Performance of Sera Prognostic’s PreTRM® Test Predictor in an Independent Large Cohort and Testing Enhancements to be Presented at the Society for Maternal-Fetal Medicine’s 40th Annual Pregnancy Meeting
SALT LAKE CITY, January 28, 2020 — Sera Prognostics, Inc., the leading women’s precision pregnancy company, today announced two podium presentations to take place at the Society for Maternal-Fetal Medicine’s 40th Annual Pregnancy Meeting in Grapevine, Texas, near Dallas, on February 3-8, 2020.
The following presentations will highlight the performance of Sera’s innovative PreTRM® biomarker testing approach:
Abstract #9: Performance of a proteomic preterm delivery predictor in a large independent prospective cohort, presented by Glenn Markenson, M.D., Professor of Obstetrics & Gynecology, Boston University School of Medicine.
– Oral Presentation – Afternoon Plenary: Thursday, February 6, 2020, 1:15PM, Grapevine B
Abstract #14: Enhanced preterm delivery predictors: verification in a large independent prospective cohort, presented by George Saade, M.D., Professor of Obstetrics and Gynecology at the University of Texas Medical Branch in Galveston.
– Oral Presentation – Afternoon Plenary: Thursday, February 6, 2020, 2:30PM, Grapevine B
About the Society for Maternal-Fetal Medicine (SMFM)
SMFM was established in 1977 to provide a forum for maternal-fetal medicine physicians and scientists to share knowledge, research methods and clinical best practices in order to improve the care of mothers and babies.
About Preterm Birth
According to the March of Dimes, of nearly 4 million babies born annually in the U.S., one in ten is born prematurely.1 Preterm birth is the leading cause of serious illness and death in newborns and results in approximately $32 billion of expense annually in the US. 2
About the PreTRM® Test
The PreTRM® test is the only clinically-validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM® test can help physicians identify, as early as 19 weeks of gestation, which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. For more information about the PreTRM® test, please visit www.PreTRM.com.
About Sera Prognostics, Inc.
Sera Prognostics is the leading health diagnostics company dedicated to improve the lives of women and babies through individualized prenatal care. For more information, please visit the company’s website at www.seraprognostics.com.